Image (5ba82783 703a 4607 Ac8c 8c15886e6621 01)
Fenofibric Acid Delayed-release Capsule, Delayed Release
Product Images NDC 42385-945
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Fenofibric Acid Delayed-release (NDC 42385-945). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Laurus Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (5ba82783 703a 4607 Ac8c 8c15886e6621 02)
Each delayed-release capsule contains choline fenofibrate, equivalent to fenofibric acid 45 mg. This medication is used to reduce cholesterol and triglycerides levels in the blood. It comes in a child-resistant package and should be stored between 20°C and 25°C, protected from moisture. It is only available with a prescription and the full prescribing information is found in the package insert. The medication is manufactured for Laurus Generics Inc. in New Jersey and manufactured by Graviti Pharmaceuticals Pvt. Ltd. in India.*
Image (5ba82783 703a 4607 Ac8c 8c15886e6621 03)
Each delayed-release capsule contains choline fenofibrate equivalent to fenofibric acid 135 mg. This 90 capsule package of Fenofibric Acid Delayed-Release Capsules is child-resistant and should be stored at 20° to 25°C (68° to 77°F), protected from moisture. The manufacturing information is provided and the full prescribing information is available in the package insert. This medication is only available by prescription.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
